ArticleCureus2026
Bilateral Total Hip Replacement for Slipped Capital Femoral Epiphysis in a Young Adult After Growth Hormone Therapy: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present the case of a 26-year-old male who developed bilateral slipped capital femoral epiphysis (SCFE) as a complication of recombinant human growth hormone (rhGH) therapy and was treated with a two-stage bilateral total hip replacement (THR). Growth hormone deficiency was due to a craniopharyngioma, for which curative neurosurgical excision led to panhypopituitarism requiring lifelong hormone replacement and continuation of rhGH therapy. The patient reported bilateral groin pain for two years before presentation; symptoms were initially attributed to short stature and spinal issues, resulting in delayed diagnosis. On presentation, there were clear signs of severe bilateral SCFE, confirmed by radiographs and CT. After shared decision-making, the patient underwent staged bilateral THR, beginning with the left hip. The case illustrates that, with advances in surgical technique and prosthetic materials, THR can be a viable option for young adults with severe SCFE, even when bilateral. It underscores the need for vigilance in monitoring patients on rhGH, particularly those with hypopituitarism, for SCFE, and highlights the importance of multidisciplinary care across endocrinology, neurosurgery, and orthopedic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.